Nad+ injections

NAD+ injections have become a fixture in longevity clinics despite relying on circuitous reasoning: the molecule is critical for cellular metabolism, cellular NAD+ declines with age, therefore restoring it intravenously should reverse aging. The gap between that logic and what the data actually show is wider than most practitioners acknowledge.

NAD+ as Cellular Currency: What the Molecule Is and Why Cells Need It

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, functioning as an electron shuttle in redox reactions that power mitochondrial respiration. Its oxidized form (NAD+) accepts electrons to become NADH, which then feeds those electrons into the electron transport chain to generate ATP. Without sufficient NAD+, glycolysis stalls, the citric acid cycle slows, and mitochondrial function deteriorates.

NAD+ also serves as a substrate for several enzyme families: sirtuins (protein deacetylases implicated in metabolic regulation and stress resistance), PARPs (DNA repair enzymes), and CD38 (a glycohydrolase that degrades NAD+ and increases with inflammation). These enzymes consume NAD+ in the process of their activity, creating a constant demand that must be replenished through biosynthesis.

The molecule can be synthesized de novo from tryptophan or recycled through salvage pathways using precursors like nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), or nicotinic acid. Most NAD+ in mammalian cells comes from the salvage pathway, which recycles nicotinamide back into NAD+ via the rate-limiting enzyme NAMPT.

The Decline Hypothesis: Why Aging Correlates With Lower NAD+ Levels

Multiple rodent studies and limited human tissue analyses confirm that NAD+ levels decline with age across several tissue types. In aged mice, skeletal muscle, liver, and brain tissue show 30-50% reductions in NAD+ compared to young controls. Human skin biopsies show similar patterns, with NAD+ levels dropping progressively after age 40.

The primary mechanism appears to be increased degradation rather than reduced synthesis. CD38 expression rises with age and chronic inflammation, hydrolyzing NAD+ at accelerated rates. Simultaneously, DNA damage accumulates, activating PARPs that consume NAD+ during repair processes. NAMPT expression also declines in some tissues, reducing the salvage pathway's capacity to recycle nicotinamide.

The hypothesis linking NAD+ decline to functional aging relies on the observation that many age-related pathologies—mitochondrial dysfunction, impaired DNA repair, reduced stress resistance—correlate with low NAD+ availability. Restoring NAD+ in aged rodents has reversed some of these phenotypes in controlled experiments, strengthening the mechanistic plausibility.

Delivery Problem: Why Oral NAD+ Fails and Injections Became the Default

NAD+ is a large, negatively charged molecule (molecular weight 663 Da) that cannot cross cell membranes intact. Oral NAD+ is rapidly degraded in the gastrointestinal tract by enzymes and gut bacteria before reaching systemic circulation. Human pharmacokinetic studies show that oral NAD+ administration produces minimal to no increase in blood NAD+ levels, even at multi-gram doses.

This bioavailability problem drove the rise of intravenous and intramuscular NAD+ administration in clinical settings. By bypassing the gut, injection theoretically delivers intact NAD+ directly into circulation. Anecdotal reports from longevity clinics describe immediate subjective effects—mental clarity, energy, mood elevation—that appear within minutes to hours of infusion, suggesting rapid central nervous system or peripheral tissue uptake.

However, the mechanism by which circulating NAD+ would enter cells remains poorly defined. The molecule still cannot cross cell membranes without transporter-mediated uptake, and no dedicated NAD+ transporter has been identified in most human tissues. Some research suggests that extracellular NAD+ may be hydrolyzed into nicotinamide or NMN at the cell surface, which can then be imported and re-synthesized into intracellular NAD+ via salvage pathways. This would make exogenous NAD+ an inefficient precursor delivery system rather than direct replenishment.

Human Evidence: What Controlled Studies Have Actually Measured

No randomized controlled trial has tested chronic NAD+ injection for any validated health outcome. The clinical evidence base consists of small pharmacokinetic studies, case series, and anecdotal reports from wellness clinics.

One published pharmacokinetic study in healthy adults (n=8) measured blood NAD+ levels following 750 mg intravenous infusion. Plasma NAD+ increased by approximately 400% within 30 minutes but returned to baseline within 3-4 hours, with a terminal half-life around 45 minutes. No intracellular NAD+ measurements were taken, and no functional outcomes were assessed. For research purposes only, this suggests that any tissue-level effects would need to occur rapidly during the brief window of elevated circulating NAD+.

Another small study (n=11) evaluated NAD+ infusions at 1000 mg over 6 weeks in participants with self-reported fatigue. Subjective energy scores improved modestly on standardized questionnaires, but the study lacked a placebo control, making it impossible to separate pharmacological effects from expectation or regression to the mean.

A case series from a longevity clinic reported improved liver enzymes and inflammatory markers in patients receiving weekly NAD+ infusions for 12 weeks, but selection bias (patients sought treatment for specific concerns) and lack of controls limit interpretation. No independent replication exists.

Precursor Alternatives: Why NMN and NR May Be More Plausible Routes

Most controlled research on NAD+ restoration has used smaller precursor molecules rather than NAD+ itself. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are both orally bioavailable and can be converted to NAD+ intracellularly through salvage pathways.

In rodent models, oral NR supplementation (400 mg/kg/day) increased liver NAD+ by 50-70% and improved mitochondrial function in aged mice. Similar results have been observed with NMN at comparable doses. These molecules likely work because they enter cells through dedicated transporters (Slc12a8 for NMN, equilibrative nucleoside transporters for NR after conversion to nicotinamide riboside) and are efficiently converted to NAD+ by intracellular kinases.

Human trials of NR (1000 mg/day for 6-12 weeks) have shown modest increases in whole blood NAD+ (10-40% above baseline) with good tolerability. One small RCT (n=30) in older adults found improved blood pressure and arterial stiffness markers compared to placebo, though effect sizes were modest and replication is pending. NMN has similar preliminary data but fewer published human trials.

The precursor approach is mechanistically cleaner: you deliver substrate that cells can convert to NAD+ as needed, rather than flooding circulation with a molecule that cannot easily enter tissues and is rapidly cleared.

Practical Research Parameters: Dosing, Administration, and Safety Signals

Published clinical protocols for NAD+ injection typically use 500-1000 mg intravenous infusion over 2-4 hours, administered 1-3 times per week. Some protocols employ intramuscular injection at 100-200 mg per dose, though absorption kinetics and tissue distribution for IM routes are poorly characterized.

The rapid infusion rate is critical. NAD+ infusions given too quickly (under 60 minutes for 1000 mg) frequently cause flushing, nausea, chest tightness, and anxiety—symptoms attributed to histamine release or direct effects on vascular smooth muscle. Slowing the infusion rate reduces these reactions but extends treatment time, making patient compliance difficult.

Half-life of circulating NAD+ post-infusion is approximately 45 minutes in most pharmacokinetic studies. This means that any cellular effects would need to occur during a brief peak exposure window, unless repeated dosing creates cumulative effects not yet documented.

Safety signals from available case series are limited to infusion reactions and rare reports of transient liver enzyme elevations. Long-term toxicity data do not exist because no multi-month controlled trials have been conducted. The molecule's role in PARP activation and sirtuin signaling raises theoretical concerns about unintended effects on DNA repair or metabolic signaling, but these remain speculative without chronic exposure studies.

Storage and handling require attention: NAD+ is light-sensitive and degrades rapidly at room temperature. Clinical-grade preparations are typically lyophilized and reconstituted immediately before infusion in sterile saline.

The Evidence Gap: What Remains Unknown and Why That Matters

The most glaring gap is the absence of any controlled trial measuring functional outcomes. Subjective reports of improved energy and mental clarity are common in clinical practice, but without placebo controls, these cannot be attributed to pharmacological effects. The brief plasma half-life and unclear cellular uptake mechanism make it difficult to predict which tissues, if any, would show sustained increases in intracellular NAD+.

No data exist on whether repeated NAD+ infusions produce cumulative effects or whether tolerance develops. The assumption that weekly infusions maintain elevated tissue NAD+ is not supported by measurements—only by extrapolation from single-dose pharmacokinetics.

The comparison to precursor molecules is also unresolved. If circulating NAD+ is mostly hydrolyzed to nicotinamide at the cell surface before uptake, then injection may function as an expensive and inconvenient delivery method for a molecule that can be taken orally. Direct head-to-head comparisons of NAD+ injection versus oral NR or NMN have not been published.

Finally, the mechanism behind acute subjective effects (mental clarity, mood elevation) remains unexplained. These effects appear too rapid to be mediated by changes in mitochondrial function or gene expression, suggesting possible direct neuromodulatory effects or placebo response.

FAQ

Q: Does intravenous NAD+ actually increase intracellular NAD+ levels?

Circulating NAD+ increases transiently after infusion, but whether this translates to higher intracellular NAD+ in target tissues is unconfirmed. NAD+ cannot cross cell membranes directly and may be degraded to smaller precursors before cellular uptake. No human study has measured tissue NAD+ content before and after injection.

Q: How does NAD+ injection compare to oral precursors like NMN or NR?

Oral NMN and NR are smaller molecules with documented cellular uptake mechanisms and have shown consistent increases in whole blood NAD+ in controlled trials. NAD+ injection bypasses gut degradation but faces unclear cellular uptake. No direct comparison study has been published, so claims of superiority for either route are speculative.

Q: Why do people report feeling immediate effects from NAD+ infusions?

The mechanism is unclear. The rapid onset (within minutes to hours) is too fast for most genomic or metabolic explanations. Possible causes include direct effects on vascular or neuronal signaling, release of stored precursors into salvage pathways, or placebo response. Controlled studies with sham infusions would clarify this.

Q: Is there any evidence NAD+ injections slow aging in humans?

No. All direct aging research has been conducted in rodents using oral precursors or genetic interventions that raise NAD+ levels. The human data on NAD+ injection consist of pharmacokinetics and uncontrolled case series. Extrapolating rodent longevity results to human injection protocols lacks empirical support.

Q: What are the known safety concerns with repeated NAD+ infusions?

Short-term infusion reactions (flushing, nausea, chest pressure) are common with rapid administration. Long-term safety data do not exist. Theoretical concerns include unintended effects on DNA repair enzyme activity and metabolic signaling, but these have not been observed in available case series lasting up to 12 weeks.

---

This content is for informational and research purposes only. NAD+ injections are not FDA-approved for any medical condition. Consult a qualified healthcare provider before considering any experimental therapy.